Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Myiasis Medication

  • Author: Adam B Blechman, MD; Chief Editor: Joe Alcock, MD, MS  more...
 
Updated: May 13, 2016
 

Medication Summary

Although the common approach for either furuncular or wound myiasis is occlusion/suffocation techniques that have been mentioned above or surgical debridement and irrigation, oral ivermectin has been proven especially helpful with oral, orbital, and nasal involvement.[1] Ivermectin has decreased the associated inflammation and the destructive process prior to debridement.[21] Thus, it has been suggested that oral ivermectin should be considered as an option for treatment of human cavitary myiasis.[22] A case has been reported of facial furuncular myiasis in a HIV-infected patient who was treated with applications of topical solution that killed the larvae and facilitated their extraction.[23]

Next

Anthelmintics

Class Summary

Neoadjuvant ivermectin therapy prior to surgical debridement has been recommended to prevent enucleation in patients with massive orbital involvement or to avoid the difficulties associated with mechanical removal of the larvae.

Ivermectin (Mectizan, Stromectol)

 

Ivermectin binds selectively with glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, causing cell death. Its half-life is 16 hours; it is metabolized in the liver.

Previous
 
Contributor Information and Disclosures
Author

Adam B Blechman, MD Resident Physician, Department of Dermatology, University of Virginia Health System

Adam B Blechman, MD is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, Medical Society of Virginia

Disclosure: Nothing to disclose.

Coauthor(s)

Barbara B Wilson, MD Edward P Cawley Associate Professor, Department of Dermatology, University of Virginia School of Medicine

Barbara B Wilson, MD is a member of the following medical societies: Alpha Omega Alpha, Medical Society of Virginia, Sigma Xi, American Academy of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Joe Alcock, MD, MS Associate Professor, Department of Emergency Medicine, University of New Mexico Health Sciences Center

Joe Alcock, MD, MS is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Robert L Norris, MD Professor, Department of Emergency Medicine, Stanford University Medical Center

Robert L Norris, MD is a member of the following medical societies: American College of Emergency Physicians, Society for Academic Emergency Medicine, International Society of Toxinology, American Medical Association, California Medical Association, Wilderness Medical Society

Disclosure: Nothing to disclose.

Acknowledgements

Eleni Grammatikopoulou, MD Visiting Physician, University of Virginia School of Medicine

Disclosure: Nothing to disclose

References
  1. Bolognia JL, Jorizzo JL, Rapini R. Cutaneous myiasis. Dermatology. 2nd ed. Mosby Elsevier; 2008. Vol 1: 1300-01.

  2. Diaz JH. The epidemiology, diagnosis, management, and prevention of ectoparasitic diseases in travelers. J Travel Med. 2006 Mar-Apr. 13(2):100-11. [Medline].

  3. Burns T, Breathnach S, Cox N, Griffiths C. Diseases caused by arthropods and other noxious animals. Rook's Textbook of Dermatology. 7th ed. Malden, MA: Blackwell Publishing; 2004. Vol 2: 33.8 - 11.

  4. Auerbach PS. Arthropod envenomation and parasitism. Wilderness Medicine. 5th ed. Philadelphia, PA: Mosby Elsevier; 2007. 969-974.

  5. Davis RF, Johnston GA, Sladden MJ. Recognition and management of common ectoparasitic diseases in travelers. Am J Clin Dermatol. 2009. 10(1):1-8. [Medline].

  6. James, WD, Berger, TG, Elston, DM. Myiasis. Andrews’ Diseases of the Skin. 11th ed. Elsevier; 2011. 438.

  7. Mandell GL, Bennett JE, Dolin R. Infectious diseases and their etiologic agents. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000. Vol 2: 2976-2979.

  8. Cestari TF, Pessato S, Ramos-e-Silva M. Tungiasis and myiasis. Clin Dermatol. 2007 Mar-Apr. 25(2):158-64. [Medline].

  9. Schwartz E, Gur H. Dermatobia hominis myiasis: an emerging disease among travelers to the Amazon basin of Bolivia. J Travel Med. 2002 Mar-Apr. 9(2):97-9. [Medline].

  10. Masoodi M, Hosseini K. External ophthalmomyiasis caused by sheepbotfly (Oestrus Ovis) larva: a report of 8 cases. Arch Iran Med. 2004. 7:136-139.

  11. Aydin E, Uysal S, Akkuzu B, et al. Nasal myiasis by fruit fly larvae: a case report. Eur Arch Otorhinolaryngol. 2006 Dec. 263(12):1142-3. [Medline].

  12. Sharma H, Dayal D, Agrawal SP. Nasal myiasis: review of 10 years experience. J Laryngol Otol. 1989 May. 103(5):489-91. [Medline].

  13. Terterov S, Taghva A, MacDougall M, Giannotta S. Posttraumatic human cerebral myiasis. World Neurosurg. 2010 May. 73(5):557-9. [Medline].

  14. Garvin KW, Singh V. Case report: cutaneous myiasis caused by Dermatobia hominis, the human botfly. Travel Med Infect Dis. 2007 May. 5(3):199-201. [Medline].

  15. Ofordeme KG, Papa L, Brennan DF. Botfly myiasis: a case report. CJEM. 2007 Sep. 9(5):380-2. [Medline].

  16. Quintanilla-Cedillo MR, Leon-Urena H, Contreras-Ruiz J, Arenas R. The value of Doppler ultrasound in diagnosis in 25 cases of furunculoid myiasis. Int J Dermatol. 2005 Jan. 44(1):34-7. [Medline].

  17. Maier H, Hönigsmann H. Furuncular myiasis caused by Dermatobia hominis, the human botfly. J Am Acad Dermatol. 2004 Feb. 50(2 Suppl):S26-30. [Medline].

  18. Brewer TF, Wilson ME, Gonzalez E, Felsenstein D. Bacon therapy and furuncular myiasis. JAMA. 1993 Nov 3. 270(17):2087-8. [Medline].

  19. Ruch DM. Botfly myiasis. Arch Dermatol. 1967 Dec. 96(6):677-80. [Medline].

  20. Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I. Myiasis. Treatment of Skin Diseases. Comprehensive Therapeutic Strategies. 2nd ed. Elesevier-Mosby; 2006. 420-421.

  21. Osorio J, Moncada L, Molano A, et al. Role of ivermectin in the treatment of severe orbital myiasis due to Cochliomyia hominivorax. Clin Infect Dis. 2006 Sep 15. 43(6):e57-9. [Medline].

  22. Costa DC, Pierre-Filho Pde T, Medina FM, Mota RG, Carrera CR. Use of oral ivermectin in a patient with destructive rhino-orbital myiasis. Eye. 2005 Sep. 19(9):1018-20. [Medline].

  23. Clyti E, Nacher M, Merrien L, et al. Myiasis owing to Dermatobia hominis in a HIV-infected subject: Treatment by topical ivermectin. Int J Dermatol. 2007 Jan. 46(1):52-4. [Medline].

Previous
Next
 
Mature larva of the Dermatobia hominis fly; rows of hooks apparent on its tapered body. Image courtesy of Kenneth E Greer.
Boil-like lesion on toe of a patient with botfly myiasis; the central punctum is apparent. Image courtesy of Kenneth E Greer.
Boil-like lesions on a patient with botfly myiasis; the central punctum is apparent. Image courtesy of Kenneth E Greer.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.